Trial Condition(s):

Erectile Dysfunction

LEVITRA® Specific Drug Use Investigation. To investigate the safety profile in combination use with alpha-blockers

Bayer Identifier:

13931

ClinicalTrials.gov Identifier:

NCT01207947

EudraCT Number:

Not Available

Study Completed

Trial Purpose

Main object is to investigate the safety profile of Levitra in combination use with alpha-blockers in patients with erectile dysfunction used in clinical practice after launch.
In the initial combination date and the first and second observation after initial combination date, number of tablets prescribed, dose of tablets and number of tablets taken until follow-up visit will be investigated. The efficacy and tolerability will be evaluated at 2 months after initial combination date.

Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
Inclusion Criteria:
 - Patients >/= 18 years
 - Enrollment within 7 days after initiation of combination use of Levitra and alpha-blockers

Trial Summary

Enrollment Goal
491
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Levitra (Vardenafil, BAY38-9456)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Japan

Status
Completed
 

Trial Design